Secured three new Top 20 porcine customers in North America.
Signed three new royalty agreements with key Chinese porcine customers
raising our total number of Chinese royalty customers to eight
Acquired Hermitage’s porcine genetics
and entered into a strategic distribution and production partnership in March 2017, with encouraging early results
Volumes growth of 8% in H2
resulting in volumes growth of 1% overall in the year (2016: 6% lower)
Full year operating profit 13% lower
(30% lower in H1)
Appointed new Chief Operating Officer
(‘COO’) of Genus ABS Dairy in January 2017
IVB continued to grow its presence with large accounts in the US and in its newly established Mexican business,
which is already performing well
Acquired the remaining 49% stake in IVB for £11.4m
in March 2017 to further accelerate integration and growth
Genus Sexed Semen (‘GSS’) technology successfully scaled up and manufacturing sexed semen in the US and India.
Sexcel™, the marketing brand of GSS, launched with customers globally on 1 September 2017 and sales have now commenced
Successfully obtained a permanent injunction against Sexing Technologies (‘ST’).
ST commenced new patent infringement litigation in June 2017 which will be vigorously defended
Launched new dairy genetic improvement programme in September 2016, De Novo,
in partnership with leading breeder De-Su with promising early results in scale and quality of genetics produced.
PRRSv resistance development programme progressing as planned:
launched a gene editing venture with new experimental facilities, optimised the molecular scissors for carrying out edits, obtained an Investigational New Animal Drug (‘INAD’) regulatory application from the US Food and Drug Administration (‘FDA’) and created the first gene edited pregnancies for the programme